Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
| Status: | Completed |
|---|---|
| Conditions: | Ocular, Ocular, Diabetes |
| Therapuetic Areas: | Endocrinology, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/1/2018 |
| Start Date: | April 17, 2017 |
| End Date: | May 31, 2018 |
More than 29 million people in the US are living with diabetes, many of whom will develop
diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye
disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual
eye screening is recommended for all diabetic patients since vision loss can be prevented
with laser photocoagulation and anti-VEGF treatment if DR is diagnosed in its early stages.
Currently, the number of clinical personnel trained for DR screening is orders of magnitude
smaller than that needed to screen the large, growing diabetic population. Therefore, to meet
this large unmet need for DR screening, a fully-automated computerized DR screening system is
necessary.
EyeArt is an automated screening device designed automatically analyze color fundus
photographs of diabetic patients to identify patients with referable or vision threatening
DED. This study is designed to assess the safety and efficacy of EyeArt.
diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye
disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual
eye screening is recommended for all diabetic patients since vision loss can be prevented
with laser photocoagulation and anti-VEGF treatment if DR is diagnosed in its early stages.
Currently, the number of clinical personnel trained for DR screening is orders of magnitude
smaller than that needed to screen the large, growing diabetic population. Therefore, to meet
this large unmet need for DR screening, a fully-automated computerized DR screening system is
necessary.
EyeArt is an automated screening device designed automatically analyze color fundus
photographs of diabetic patients to identify patients with referable or vision threatening
DED. This study is designed to assess the safety and efficacy of EyeArt.
This is a prospective, multi-center, observational study to assess the safety and efficacy of
EyeArt in screening for DR.
This study will enroll up to 940 subjects who meet the eligibility criteria at eye care
practices and primary/diabetes care practices. Subjects will undergo fundus photography per
the EyeArt photography manual using commercially available, Food and Drug Administration
(FDA) cleared, non-mydriatic fundus cameras.
Additionally, after dilation, the subject will undergo clinical reference standard
photography by photographers certified to obtain photographs for clinical reference standard
grading.
The EyeArt screening results on photographs obtained per the EyeArt photography manual will
be compared with the clinical reference standard grading to evaluate the sensitivity and
specificity of the EyeArt device.
The study will be conducted in accordance with applicable regulatory requirements and
established rules for Good Clinical Practice (GCP). Study sites will be chosen to meet the
study requirements.
Each study site will be visited periodically by the Study Monitor who will ascertain that all
aspects of the Study Protocol are complied with and that the conduct of the study conforms to
applicable regulatory requirements and established GCP rules.
At the time of each monitoring visit, the Study Monitor will review the completed case report
forms (CRFs) to ascertain that all items have been completed and that the data provided are
accurate and obtained in the manner specified in the protocol.
The Study Monitor will also check that the data in the CRF are consistent with the clinical
records (Source Data Verification) and that study results are recorded completely and
correctly. The Study Monitor will check on the reporting of adverse events (AEs).
All subject data will be captured utilizing a 21 CFR Part 11 compliant database. Electronic
case report forms (eCRFs) will be source document verified by designated study monitors. Data
entry of subject data will be performed by approved trained Site Personnel. Approved Site
Personnel will have a user specific log-in name and password to access the electronic data
capture (EDC) system in order to enter study data.
The EyeArt device will be finalized and frozen before the first subject is enrolled and a
copy will be placed in a version-controlled system. Evidence that Eyenuk does not have direct
access to the study data before data lock will include documentation, logs, and audit
reports.
EyeArt in screening for DR.
This study will enroll up to 940 subjects who meet the eligibility criteria at eye care
practices and primary/diabetes care practices. Subjects will undergo fundus photography per
the EyeArt photography manual using commercially available, Food and Drug Administration
(FDA) cleared, non-mydriatic fundus cameras.
Additionally, after dilation, the subject will undergo clinical reference standard
photography by photographers certified to obtain photographs for clinical reference standard
grading.
The EyeArt screening results on photographs obtained per the EyeArt photography manual will
be compared with the clinical reference standard grading to evaluate the sensitivity and
specificity of the EyeArt device.
The study will be conducted in accordance with applicable regulatory requirements and
established rules for Good Clinical Practice (GCP). Study sites will be chosen to meet the
study requirements.
Each study site will be visited periodically by the Study Monitor who will ascertain that all
aspects of the Study Protocol are complied with and that the conduct of the study conforms to
applicable regulatory requirements and established GCP rules.
At the time of each monitoring visit, the Study Monitor will review the completed case report
forms (CRFs) to ascertain that all items have been completed and that the data provided are
accurate and obtained in the manner specified in the protocol.
The Study Monitor will also check that the data in the CRF are consistent with the clinical
records (Source Data Verification) and that study results are recorded completely and
correctly. The Study Monitor will check on the reporting of adverse events (AEs).
All subject data will be captured utilizing a 21 CFR Part 11 compliant database. Electronic
case report forms (eCRFs) will be source document verified by designated study monitors. Data
entry of subject data will be performed by approved trained Site Personnel. Approved Site
Personnel will have a user specific log-in name and password to access the electronic data
capture (EDC) system in order to enter study data.
The EyeArt device will be finalized and frozen before the first subject is enrolled and a
copy will be placed in a version-controlled system. Evidence that Eyenuk does not have direct
access to the study data before data lock will include documentation, logs, and audit
reports.
Inclusion Criteria:
- A diagnosis of diabetes mellitus;
- Understanding of study and provision of written informed consent; and
- 18 years of age or older.
Exclusion Criteria:
- Persistent visual impairment in one or both eyes;
- History of macular edema or retinal vascular (vein or artery) occlusion;
- History of ocular injections, laser treatment of the retina, or intraocular surgery
other than cataract surgery without complications;
- Subject is contraindicated for fundus photography (for example, has light
sensitivity);
- Subject has contraindications for mydriatic medications or is unwilling or unable to
dilate;
- Subject is currently enrolled in an interventional study of an investigational device
or drug; or
- Subject has a condition or is in a situation which in the opinion of the Investigator,
might confound study results, may interfere significantly with the subject's
participation in the study, or may result in ungradable clinical reference standard
photographs.
We found this trial at
1
site
Click here to add this to my saved trials
